The US Food and Drug Administration’s review and approval of Moderna, Inc.’s COVID-19 vaccine Spikevax reflected the uncertainties of the evidence amid an evolving pandemic, notably the emergence of the Omicron variant.
The biologics license application was submitted to the agency on 24 August, at which time the Delta variant was predominant in the US
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?